Skip to main content
main-content

16.06.2017 | Basic Science Foundations in Colorectal Cancer (J Roper, Section Editor) | Ausgabe 4/2017

Current Colorectal Cancer Reports 4/2017

Resistance Mechanisms to Colorectal Cancer Therapeutics and the Clinical Implications

Zeitschrift:
Current Colorectal Cancer Reports > Ausgabe 4/2017
Autoren:
Philip Emmerich, Linda Clipson, Dustin A. Deming
Wichtige Hinweise
This article is part of the Topical Collection on Basic Science Foundations in Colorectal Cancer

Abstract

Purpose of Review

Colorectal cancer (CRC) is a leading cause of cancer-related death and additional treatment options are urgently needed. Cytotoxic chemotherapy has been the mainstay of treatment options for patients for many years, including FOLFOX (leucovorin, 5-fluorouracil (5-FU), and oxaliplatin) or FOLFIRI (5-FU, leucovorin, and irinotecan) Here we review the current clinical use of systemic therapies for metastatic CRC and mechanisms of resistance to these agents.

Recent Findings

Biologic therapies, including anti-angiogenic and anti-epidermal growth factor monoclonal antibodies, have shown increased efficacy for patients with metastatic CRC. Most recently, immunotherapies have also been an option for some patients.

Summary

Identification of molecular markers predictive of response or resistance has led to enhanced ability to treat patients with metastatic CRC in a more personalized fashion.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2017

Current Colorectal Cancer Reports 4/2017 Zur Ausgabe

Basic Science Foundations in Colorectal Cancer (J Roper, Section Editor)

Inflammation and Colorectal Cancer

Systemic Therapies in Colorectal Cancer (RD Kim, Section Editor)

Treatment of Refractory Colorectal Cancer: Regorafenib vs. TAS-102

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Adenomatous Polyposis Syndromes: Familial Adenomatous Polyposis and MutYH-Associated Polyposis

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

Clinical Target Volume Definition in Preoperative Radiotherapy of Rectal Carcinoma: a Systematic Review

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Quality Colorectal Cancer Screening: Endoscopic Performance Measures and Beyond

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise